Zelluna ASA (OSL:ZLNA)

Norway flag Norway · Delayed Price · Currency is NOK
16.00
0.00 (0.03%)
Mar 5, 2026, 10:40 AM CET
-23.81%
Market Cap 420.21M
Revenue (ttm) n/a
Net Income (ttm) -140.71M
Shares Out 26.27M
EPS (ttm) -7.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 368
Average Volume 27,964
Open 16.00
Previous Close 16.00
Day's Range 16.00 - 16.00
52-Week Range 8.20 - 22.50
Beta n/a
RSI 53.43
Earnings Date Feb 12, 2026

About Zelluna ASA

Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101). The company was founded in 2016 and is based in Oslo, Norway. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 24
Stock Exchange Oslo Børs
Ticker Symbol ZLNA
Full Company Profile

Financial Performance

Financial Statements

News

Q4 2025 Zelluna ASA Earnings Presentation Transcript

Q4 2025 Zelluna ASA Earnings Presentation Transcript

20 days ago - GuruFocus

Zelluna ASA (OSL:ZLNA) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Insights

Zelluna ASA (OSL:ZLNA) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Insights

4 months ago - GuruFocus

Q3 2025 Zelluna ASA Earnings Call Transcript

Q3 2025 Zelluna ASA Earnings Call Transcript

4 months ago - GuruFocus